Mark McHale, Ph.D.

Chief Scientific Officer

Mark McHale, PhD, has broad pharma and biotech experience, having spent decades working within the industry in various capacities. Prior to joining Oak Hill Bio, Dr. McHale was Chief Operating Officer at Theramyc, a biotech based in the United Kingdom and Australia. He arrived at Theramyc after serving as Chief Development Officer and Head of R&D at Aslan Pharmaceuticals, which he helped found. Over the course of his career, Dr. McHale has held leadership roles at AstraZeneca and SmithKline Beecham (now GlaxoSmithKline Plc.). At AstraZeneca, he worked for many years as Head of Molecular Sciences, Respiratory & Inflammation, where he led all new target identifications in asthma. At SmithKline Beecham, he supported lead optimization projects in serotonin and dopamine receptors. Dr. McHale received his PhD in Molecular Biology from the University of East Anglia and his bachelor’s in Genetics from the University of London.